XML 53 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment And Significant Customer Information
 9 Months Ended
Sep. 30, 2014
Segment and Significant Customer Information [Abstract]  
SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION

14. SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION

 

Pursuant to Codification Topic 280, Segment Reporting, we operate in one reportable business segment, that being the development, acquisition, manufacture and sale of products that improve animal health and productivity in the dairy and beef industries. Almost all of our internally funded product development expenses are in support of such products. Our primary customers for the majority of our product sales (84% and 89% for the three-month periods ended September 30, 2014 and 2013, respectively, and 82% and 84% for the nine-month periods ended September 30, 2014 and 2013, respectively) are in the U.S. dairy and beef industries. Product sales to international customers, who are also in the dairy and beef industries, aggregated 11% of our total product sales for both of the three-month periods ended September 30, 2014 and 2013, and 13% and 14% of our total product sales for the nine-month periods ended September 30, 2014 and 2013, respectively. The percentage of our total sales that were made to significant customers that amounted to 10% or more of total product sales are detailed in the following table:

 

  

For the Three-Month Periods Ended

September 30,

  

For the Nine-Month Periods Ended

September 30,

 
  2014  2013  2014  2013 
Animal Health International, Inc.  34%  40%  37%  38%
MWI Veterinary Supply Company(1)  23%  21%  22%  22%

 (1) Assumes the acquisition of IVESCO by MWI Veterinary Supply Company (which closed as of November 1, 2013) had closed as of January 1, 2013.

 

Accounts receivable due from significant customers that amounted to 10% or more of total trade accounts receivable are detailed in the following table:

 

  As of 
September 30, 2014		  As of 
December 31, 2013		 
MWI Veterinary Supply Company  33%  26%
Animal Health International, Inc.  25%  39%
Robert J. Matthews Company  14%  10%